CSL News: Why Shares of uniQure Rose 14.61% on Wednesday - 24th Nov 2022, 9:30am

[annb0t]

Shares of uniQure (NASDAQ: QURE) climbed 14.61% on Wednesday. The stock jumped after the Food and Drug Administration (FDA), on Tuesday, approved Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B. It was developed by uniQure, but CSL will commercialize the therapy. Hemophilia B, also known as Christmas disease, is rare.

Continue reading

>>> Read more: Why Shares of uniQure Rose 14.61% on Wednesday